AstraZeneca has committed a record $4.5 billion, an increase of $500 million, to build a state-of-the-art complex that will serve as the foundation for the company’s vital drug production in the United States if it expands its planned manufacturing site in Virginia. AstraZeneca’s greatest investment to date is expected to generate about 3,600 jobs in the Commonwealth.
Part of the pharmaceutical giant’s previously announced $50 billion commitment to research and development and American manufacturing, the new facility will be situated at Rivanna Futures in Albemarle County, close to Charlottesville.
Expanding Scope to Combat Cancer and Metabolic Disease
Manufacturing capabilities for several of the company’s most major therapeutic areas are now part of the facility’s much increased scope. The expanded plans will also include advanced manufacturing for AstraZeneca’s leading antibody drug conjugate (ADC) cancer portfolio. Initially, the plans were centered on weight management and metabolic portfolio, including drug substance manufacture for drugs including oral GLP-1, baxdrostat, and oral PCSK9.
By protecting crucial supply chains, the action is strategically intended to boost national security and health sovereignty by bringing critical drug manufacturing closer to the American patient population. The facility will use state-of-the-art technology, such as artificial intelligence (AI), automation, and data analytics, to maximize production efficiency when it opens in the next four to five years.
Read More: AstraZeneca Announces $50 Billion Investment in the United States
With our $4.5 billion investment in Virginia, the largest in AstraZeneca’s history, we are not only building a state-of-the-art manufacturing facility, but also driving life sciences innovation and economic growth. This new facility will create thousands of jobs and strengthen America’s national security and health sovereignty. I also want to thank Governor Youngkin and his team for their energy and vision. We have found in Virginia an amazing team that moves at incredible speed to build a better future for this Commonwealth and the American people.
Pascal Soriot
Scope of Operations and Technology
Two important therapeutic areas are now included in the manufacturing scope of the Virginia facility:
- Portfolio for Metabolic and Weight Management: The facility will manufacture therapeutic substances for products such as oral PCSK9, oral GLP-1, baxdrostat, and other combination small molecule drugs.
- Expansion of the Oncology Portfolio: This now encompasses cutting-edge production of AstraZeneca’s top antibody drug conjugate (ADC) cancer therapies.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Employment and Economic Impact
It is anticipated that the project will generate 3,600 jobs in total, greatly enhancing Virginia’s area economy:
- Among the 600 Direct & Highly Skilled Jobs are scientists, engineers, and process facilitators. One hundred more highly skilled positions were added as a result of the scope extension.
- Construction & Indirect Jobs (3,000): These positions, which include engineers, skilled craftspeople, and construction workers, will assist with the facility’s building phase.
- To obtain the project, Albemarle County, the General Assembly’s Major Employment and Investment Project Approval Commission, and the Virginia Economic Development Partnership (VEDP) worked together.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
